Keywords: fda, panel, backs, approval, gw, remifentanil, april

FDA Panel Backs Approval Of GW's Remifentanil

Article | 06 May 1996

Print This

On April 30, Glaxo Wellcome's new opioid analgesic Ultiva (remifentanil hydrochloride) was recommended for approval by the US Food and Drug ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in